RT Journal文章SR电子T1次优依从性CPAP治疗对阻塞性睡眠呼吸暂停的症状：随机，双盲，受控试验JF欧洲呼吸期刊Jo EUR Respir J FD欧洲呼吸协会SP 1901526 Do 10.1183 / 13993003.01526-2019188bet官网地址A1 Gaisl，Thomas A1 Rejmer，Protazy A1 Thiel，Sira A1 Haile，Sarah R. A1 Oswald，Martin A1 Roos，Malgorzata A1 Bloch，Konrad E. A1 Stradling，John R. A1 Kohler，Malcolm YR HTTP：// ERJ.ERSJOURNALS.com / CONTER / 2019/1293003.01526-2019.Stract AB简介持续正气道压力（CPAP）目前是患者患者嗜睡选择的选择，但是坚持不懈经常被认为是次优。我们调查了次优CPAP使用对OSA患者客观和主观嗜睡参数的影响。本2周，平行，双盲，随机对照试验我们注册了中度至严重的OSA患者的过度前进- 处理日间嗜睡（epworth-睡眠 - 尺度[ESS]得分> 10分），他们在至少12个月内有次优CPAP遵守（意味着每晚3-4小时）。患者通过最小化分配给子治疗性CPAP（“假CPAP”）或CPAP（治疗CPAP）的延续。历史前沿的贝叶斯分析计算出优势的后验概率。2016年5月和2018年11月之间的结果，总共分配了57例患者（60±8岁，79％的男人，93％的白种人），52人完成了这项研究（每只手臂中的50％）包括在最终分析中。与持续治疗CPAP相比，未经调整的ESS-Score增加在假CPAP-Group中增加了+ 2.4点（95％CI + 0.6至+ 4.2; p = 0.01）。SheS CPAP的优越性的概率为ESS的90.4％，90.1％用于收缩压，舒张血压的80.3％。结论中度至严重的OSA和白天嗜睡的患者仍然从次优CPAP获得了大量的利益 adherence, albeit not as much as they might get if they adhered more. Whether a similar statement can be made for even lower adherence levels remains to be established in future trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Gaisl reports personal fees from Bayer AG (consulting), outside the submitted work.Conflict of interest: Dr. Rejmer has nothing to disclose.Conflict of interest: Dr. Thiel has nothing to disclose.Conflict of interest: Dr. Haile has nothing to disclose.Conflict of interest: Dr. Osswald has nothing to disclose.Conflict of interest: Dr. Roos has nothing to disclose.Conflict of interest: Dr. Bloch has nothing to disclose.Conflict of interest: Dr. Stradling reports personal fees from Bayer AG, personal fees from ResMed, outside the submitted work.Conflict of interest: Dr. Kohler reports personal fees from Bayer AG, grants from University of Zurich, grants from Lunge Zurich, outside the submitted work.